Not yet recruitingObservationalLast updated Aug 12, 2026

Updates and Insights on HER2 in Breast Cancer in Sohag Governorate

Updates and Insights on Human Epidermal Growth Factor Receptor 2 (HER2) in Breast Cancer in Sohag Governorate

Overview

ClinicalTrials.gov ID: NCT07758127
Lead Sponsor: Sohag UniversityOTHER
Brief Summary: To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.

To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes

To access interobserval agreement in HER2 score interpretation

Status

Study Record Dates

NCT07056205Enrolling by invitation

Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.

NCT04284631Completed

Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.

NCT07416409Completed

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

NCT07024225Recruiting

Colorectal Cancers :A Retrospective Study

NCT06055647Completed

HER-2 Expression in Pancreatic Duct Adenocarcinoma

NCT06188494Completed

UNFOLD Study Egypt